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Abstract
Introduction The endothelial specific angiopoietin (Ang)-Tie2
ligand-receptor system has been identified as a non-redundant
mediator of endothelial activation in experimental sepsis.
Binding of circulating Ang-1 to the Tie2 receptor protects the
vasculature from inflammation and leakage, whereas binding of
Ang-2 antagonises Tie2 signalling and disrupts endothelial
barrier function. Here, we examine whether circulating Ang-1
and/or Ang-2 independently predict mortality in a cohort of
critically ill medical patients.
Methods Circulating vascular endothelial growth factor (VEGF),
Ang-1 and Ang-2 were prospectively measured in sera from 29
healthy controls and 43 medical ICU patients by
immunoradiometric assay (IRMA) and ELISA, respectively.
Survival after 30 days was the primary outcome studied.
Results Median serum Ang-2 concentrations were increasingly
higher across the following groups: healthy controls, patients
without sepsis, patients with sepsis and patients with septic
shock. In contrast, Ang-1 and VEGF concentrations were
significantly lower in all patient groups compared with healthy
controls. Ang-2 correlated with partial pressure of oxygen in
arterial blood (PaO2)/fraction of inspired oxygen (FiO2), tissue
hypoxia, Sequential Organ Failure Assessment (SOFA) and
Physiology and Chronic Health Evaluation II (APACHE II) score.
Multivariate Cox regression analyses confirmed a strong
independent prognostic impact of high Ang-2 as a novel marker
of 30-day survival.
Conclusions A marked imbalance of the Ang-Tie system in
favour of Ang-2 is present in critically ill medical patients. Our
findings highlight the independent prognostic impact of
circulating Ang-2 in critical illness. Ang-2 may be used as a
readily available powerful predictor of outcome and may open
new perspectives to individualise treatment in the ICU.
Introduction
In critically ill patients, impaired vascular barrier function is a
life-threatening feature that is causally determined by the acti-
vational state of the endothelial layer. In response to numerous
different stimuli, 'quiescent' endothelial cells (anti-coagulant,
anti-adhesive) undergo dramatic phenotypic changes towards
an 'activated', pro-coagulant, pro-adhesive state, which is par-
alleled by disassembly of adherence junctions (e.g. VE-cad-
herin) and myosin driven cell contraction, resulting in inter-
endothelial gap formation [1,2]. This highly regulated cascade
of events results in net extravasation of fluid, a profound
decrease in systemic vascular tone, collapse of the microcir-
culation and subsequent distributive shock, acute respiratory
distress syndrome (ARDS) and eventually multiple organ dys-
function syndrome (MODS) [1,3-5]. Thus, an important goal in
critical care medicine is to develop novel diagnostic and ther-Page 1 of 9
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the intensive care unit (ICU).
In 1996, Davis and colleagues discovered the angiopoietin
(Ang)-Tie2 ligand-receptor system as the second class of vas-
cular-specific receptor tyrosine kinases (the first being the vas-
cular endothelial growth factor (VEGF)/VEGF-receptor
system) [6]. Classically understood as an important regulator
in vessel maturation and remodelling, recent studies demon-
strated that the Ang-Tie2 system not only regulates angiogen-
esis, but also controls endothelial inflammation in a non-
redundant manner [7-9].
Ang-1 and Ang-2 are antagonistic ligands that bind with simi-
lar affinity to the extracellular domain of the Tie2 receptor,
which is almost exclusively expressed by endothelial cells.
Binding of the agonist Ang-1 to the Tie2 receptor promotes
vessel integrity, inhibits vascular leakage and suppresses
inflammatory gene expression [10,11]. Constitutively
expressed by pericytes and vascular smooth muscle cells,
Ang-1 provides a stabilisation signal [8,12,13]. In contrast,
Ang-2 inhibits binding of Ang-1 to Tie2, thereby disrupting
protective Tie2 signalling [10,13-15]. Ang-2, which is consid-
ered the dynamic part of the Ang-Tie2 ligand-receptor, is
stored and rapidly released by endothelial Weibel-Palade bod-
ies [8]. Depending on the context, Ang-2 may act as a Tie2
agonist, especially in the presence of VEGF [16-18]. Intrigu-
ingly, VEGF itself was first identified and characterised as a
potent stimulator of endothelial permeability and elevated cir-
culating levels of VEGF seem to correlate with severity of sep-
sis and septic shock [19-21].
So far, several studies have investigated circulating Ang-1 and
Ang-2 levels in critically ill patients [21-26]. Elevated Ang-2
concentrations correlate with the severity of illness as
assessed by injury severity score [22], organ failure index [24],
Acute Physiology and Chronic Health Evaluation (APACHE) II
scores and Sequential Organ Failure Assessment (SOFA)
scores [23,25,26]. In a recent study, we established and vali-
dated two novel immunoassays for the detection of circulating
Ang-1 and Ang-2 in critically ill patients [27]. Despite the
growing body of evidence indicating a role for Ang-2 as a
mediator in critically illness, the value of Ang-2 as a predictive
marker of outcome is poorly defined.
The aim of this study was to investigate the independent value
of circulating Ang-1 and Ang-2 as predictors of outcome in
critically ill medical patients.
Materials and methods
Patients
From the ICU at the Internal Medicine Department at Hannover
Medical School, Germany, a tertiary care university hospital,
43 patients were enrolled at the time of ICU admission and
studied prospectively. Patients were subdivided into the fol-
lowing groups: severe sepsis (n = 12), septic shock (n = 17)
and critically ill patients (n = 14) with no evidence or suspicion
of bacterial infection or sepsis (SCCM/ESICM/ACCP/ATS/
SIS definitions [28]). Enrollment was performed in a consecu-
tive fashion after obtaining written informed consents from the
patients or their legal representatives. If the patient was recov-
ering and able to communicate, he/she was informed of the
study purpose and consent was required to further maintain
status as study participant. The study was performed in
accordance with the declaration of Helsinki and approved by
the institutional review board. There were no co-morbidities
that led to exclusion, except for age younger than 18 years or
older than 75 years, being pregnant and having a malignant
neoplasm.
Subjects were ventilated in accordance with the ARDSNet-
derived protocol [29]. In 29 patients, invasive haemodynamic
monitoring was performed by the Pulse contour Continous
Cardiac Output (PiCCO) system (Pulsion Medical Systems,
Munich, Germany) in addition to standard techniques. This
device enables invasive on-line monitoring of several haemo-
dynamic parameters, such as mean arterial pressure (MAP),
heart rate (HR), cardiac index (CI), systemic vascular resist-
ance index (SVRI), intrathoracic blood volume index (ITBVI)
and extravascular lung water index (EVLWI), based on a
transpulmonary thermodilution technique [30,31]. All relevant
laboratory and medical data, including APACHE II [32] and
SOFA scores [33], were obtained at the time of enrollment.
Detailed patients' characteristics, including demographic, clin-
ical and laboratory parameters, are shown in Table 1.
Controls
Twenty-nine age- and gender-matched healthy volunteers
from the Hannover Medical School staff served as controls (16
males, 13 females; age 58 (25 to 73 years)).
Sampling
Serum samples for quantification of Ang-1, Ang-2 and VEGF
were obtained at the time of enrollment, immediately placed on
ice, centrifuged and stored at -80°C. All measurements were
performed in a blinded fashion by the same investigator.
Quantification of circulating Ang-1 and Ang-2
Ang-1 and Ang-2 were measured by in-house Immuno Radio-
metric Sandwich Assay (IRMA) and ELISA, respectively as
previously described [27,34]. Polyclonal, anti-human Ang-1
affinity purified goat immunoglobulin (Ig) G and a monoclonal
anti-human Ang-1 mouse antibody were obtained from R&D
Systems (R&D, Oxford, UK). Recombinant human Ang-1 was
purchased from Sigma-Aldrich (Sigma-Aldrich, Munich, Ger-
many). Recombinant human Ang-2 monoclonal Ang-2 anti-
body and anti-Ang-2 antibody were purchased from R&D
Systems (R&D, Oxford, UK).Page 2 of 9
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Serum VEGF was measured using a sandwich ELISA kit
according to the manufacturer's instructions (R&D Systems,
Minneapolis, USA). This assay measures biologically active
VEGF121 and VEGF165.
Statistical analysis
Differences between patients and healthy controls were eval-
uated using a non-parametric Kruskal-Wallis test. The Mann-
Whitney rank sum test was used for comparison between indi-
vidual groups. Correlations between variables were assessed
by the Spearman rank correlation coefficient. Pearson's corre-
lation coefficient and linear regression analysis was performed
after logarithmic transformation of Ang-2 values (logAng-2).
The primary outcome studied was 30-day survival and was cal-
culated from the day of ICU admission to death. Patients who
survived the follow-up period were censored at day 30. Param-
eters independently associated with survival were identified by
univariate and multivariate Cox proportional hazards models.
Variables found to be statistically significant at a 10% level in
the univariate analysis were included in the multivariate model
using backward elimination. Different models were estab-
lished, incorporating either Ang-2, logAng-2 or the Ang-2/
Ang-1 ratio, respectively. Two-sided p-values < 0.05 were
considered statistically significant for all statistical procedures
used. The distribution of the time-to-event variables were esti-
mated using the Kaplan-Meier method with log-rank testing.
Receiver operator characteristics (ROC) procedures were
used to identify optimal cut-off values. Data are displayed as
median and range (minimum to maximum) unless otherwise
stated. All statistical analyses were performed with the SPSS
Table 1
Demographic, clinical and laboratory characteristics of patients
Characteristics Total Non-septic patients Severe sepsis Septic shock
Number of patients 43 14 12 17
Male 25 (59%) 6 (43%) 5 (42%) 14 (82%)
Female 18 (41%) 8 (57%) 7 (58%) 3 (18%)
Age (years, median (min – max) 51 (21 to 73) 59 (37 to 73) 51 (43 to 69) 51 (39 to 64)
Reason for medical ICU admission
Pulmonary 15 (35%) 4 (29%) 3 (25%) 8 (47%)
Abdominal 10 (23%) 2 (14%) 4 (33%) 4 (24%)
Urogenital/retroperitoneal 3 (7%) 1(7%) 2 (17%) 0 (0%)
Cardiac 4 (9%) 3 (21%) 0 (0%) 1 (6%)
Cerebrovascular 4 (9%) 4 (29%) 0 (0%) 0 (0%)
Bloodstream infections 4 (9%) 0 (0%) 2 (17%) 2 (12%)
Miscellaneous 3 (7%) 0 (0%) 1 (8%) 2 (12%)
Mean arterial pressure (mmHg) 70 (40 to 96) 67 (53 to 84) 76 (67 to 91) 72 (60 to 81)
Heart rate (bpm) 100 (50 to 145) 102 (88 to 120) 90 (78 to 110) 106 (87 to 129)
Noradrenaline (μg/kg/min) 0.19 (0.0 to 1.96) 0.025 (0.0 to 0.07) 0.115 (0.02 to 0.18) 0.57 (0.32 to 0.77)
Mechanically ventilated, no. 36 (84%) 6 (43%) 12 (100%) 17 (100%)
FiO2 (%) 45 (26 to 100) 40 (34.53) 42 (35 to 62) 50 (59 to 60)
PaO2/FiO2 240 (68 to 640) 269 (218 to 367) 200 (130 to 257) 190 (138 to 272)
CRP (mg/L) 129 (51 to 268) 117 (5 to 194) 172 (79 to 304) 136 (54 to 282)
Creatinine (mmol/L) 251 (160 to 401) 116 (54 to 302) 354 (210 to 431) 273 (188 to 427)
Lactate (mmol/L) 1.9 (1.2 to 2.9) 1.3 (0.9 to 2.0) 1.6 (1.0 to 2.1) 2.9 (2.1 to 10.6)
APACHE II score 30 (6 to 48) 26 (17 to 30) 32 (25 to 35) 32 (29 to 38)
SOFA score 16 (1 to 22) 8 (4 to 11) 17 (14 to 20) 18 (16 to 20)
Mortality 25 (59%) 4 (29%) 8 (67%) 13 (77%)
APACHE II = Acute Physiology And Chronic Health Evaluation score; CRP = C-reactive protein; FiO2 = fraction of inspired oxygen; ICU = 
intensive care unit; PaO2 = partial pressure of oxygen in arterial blood; SOFA = Sequential Organ Failure Assessment score.Page 3 of 9
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Prism software (GraphPad Prism Software Inc. San Diego,
California, USA).
Results
Decreased Ang-1 and VEGF concentrations and 
increased Ang-2 concentrations in critically ill medical 
patients
Ang-1 concentrations in critically ill non-septic patients (0.8
ng/ml, 0.5 to 11.7 ng/ml), patients with severe sepsis (0.5 ng/
ml, 0.3 to 18.8 ng/ml) and patients with septic shock (0.9 ng/
ml, 0.3 to 5.5 ng/ml were markedly decreased compared with
healthy controls (56.4 ng/ml, 34.5 to 71.3 ng/ml, p < 0.0001)
(Figure 1a). Ang-1 concentrations were no different between
severe sepsis, septic shock and non-septic patients.
In contrast, median serum Ang-2 concentrations were consist-
ently increased in critically ill non-septic patients (2.8 ng/ml,
1.0 to 9.0 ng/ml), in patients with severe sepsis (16.45 ng/ml,
2.7 to 39.7 ng/ml) and patients with septic shock (28.1 ng/ml,
3.7 to 72.6 ng/ml), compared with healthy controls (0.9 ng/ml,
0.3 to 2.6 ng/ml; all p < 0.0001 versus controls) (Figure 1b).
Ang-2 was higher in patients with sepsis compared with non-
septic patients (both p < 0.0001). Ang-2 concentrations were
not different between patients with severe sepsis and septic
shock (p = 0.12). Ang-1 and Ang-2 concentrations were nei-
ther linked to gender (Mann-Whitney test: p = 0.42 and p =
0.51) nor age (Spearman correlation: p = 0.83 and p = 0.24).
VEGF concentrations were markedly lower in critically ill non-
septic patients (43.5 pg/ml, 4.1 to 200.0 pg/ml), patients with
severe sepsis (112.7 pg/ml, 34.9 to 569.1 pg/ml) and patients
with septic shock (70.5 pg/ml, 3.7 to 179.9 pg/ml compared
with healthy controls (515.5 pg/ml, 280.6 to 1294.0 pg/ml, all
p < 0.0001) (Figure 1c). VEGF concentrations were no differ-
ent between patients with severe sepsis, patients with septic
shock and non-septic controls. VEGF concentrations were not
linked to gender (p = 0.67) and did not correlate with age (p
= 0.33).
Circulating Ang-2 concentrations correlate with SOFA 
and APACHE II scores
Linear regression analysis detected a strong association of
logAng-2 concentration with APACHE II scores (r2 = 0.28, p
= 0.0003) and SOFA scores (r2 = 0.62, p < 0.0001) (Figures
2a,b; n = 43). Hypoxia has been shown to induce the release
of Ang-2 from endothelial cells in preclinical models [35,36].
Of note, a strong correlation between Ang-2 concentrations
and lactate levels as a surrogate marker for tissue hypoper-
fusion and microcirculatory tissue hypoxia was detected (r2 =
0.25, p = 0.0007). Neither Ang-1 nor VEGF correlated with
APACHE II scores, SOFA scores or C-reactive protein (CRP)
levels.
Figure 1
Box plots of results in healthy controls and study patients lots of results in healthy controls and study pa ients. Circulat-
ing (a) Angiopoietin (Ang) 1, (b) Ang-2 and (c) vascular endothelial 
growth factor (VEGF) serum concentrations in healthy controls (n = 
29), critically ill patients without infection (no sepsis; n = 14), patients 
with severe sepsis (n = 12) and septic shock (n = 17). Horizontal bars 
indicate median values.Page 4 of 9
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Pre-clinical models have impressively demonstrated that the
intact Ang-1/Tie2 signalling protects from ARDS in experimen-
tal sepsis [36-38]. We therefore examined the association
between several parameters of haemodynamic and pulmonary
function with circulating Ang-1, Ang-2 and VEGF levels. Of
those, only Ang-2 showed an inverse correlation with partial
pressure of oxygen in arterial blood (PaO2)/fraction of inspired
oxygen (FiO2) (r2 = -0.31; p = 0.046), and PaO2 (r2 = -0.35; p
= 0.023) as surrogate markers for ventilator support and pul-
monary function. No association was seen for peak airway
pressure (p = 0.6) or positive end expiratory pressure levels (p
= 0.45). In addition to routine invasive haemodynamic monitor-
ing (n = 43), 29 ventilated patients without atrial fibrillation
qualified for detailed haemodynamic assessment by transpul-
monary thermodilution technique (PiCCO system). Surpris-
ingly, none of the measured angiogenic factors correlated with
any of the haemodynamic parameters (MAP, CI, EVLWI, ITBVI,
SVRI, vasopressor dose or central venous pressure; data not
shown). The same results were obtained for invasive routine
monitoring in all 43 patients (data not shown).
Circulating Ang-2 predicts mortality in critically ill 
patients
To determine the relation between Ang-2 levels at admission
and mortality, we initially performed univariate Cox proportional
hazards analyses. In our whole cohort of critically ill medical
patients, age, gender or the presence of sepsis did not show
prognostic significance for survival (Table 2). The same was
true for MAP, HR, CVP, urine output, noradrenaline dose,
FiO2, PaO2/FiO2, thrombocytes, bilirubin, CRP and VEGF
(Table 2). Among the tested variables, lactate (p = 0.006),
APACHE II score (p = 0.013), SOFA score (p = 0.038) and
the amount of circulating Ang-2 (p = 0.001) displayed prog-
nostic significance (Table 2).
Subsequently, the following variables were found to be statis-
tically significant at a 10% level in the univariate analysis and
subjected to multivariate Cox regression analysis: lactate,
APACHE II score, SOFA score and circulating Ang-2 (Table
2). Except for Ang-2 (p = 0.002), all other variables did not
remain significant in the multivariate setting (lactate (p =
0.111), APACHE II score (p = 0.154), SOFA score (p =
0.167)). The same results were obtained when either logAng-
2 (p = 0.003) or the Ang-2/Ang-1 ratio (p = 0.036) were
tested instead of Ang-2 (Table 2). Thus, circulating Ang-2 was
identified as a strong, independent prognostic factor for 30-
day survival in our cohort of critically ill medical patients. Given
the context-dependent synergistic effects of Ang-2 and VEGF,
we analysed various ratios incorporating Ang-1, Ang-2 and
VEGF (data not shown). Except for the Ang-2/Ang-1 ratio,
none of these models reached statistical significance (Table
2).
Ang-2 yielded an area under the ROC curve (AUC) value of
0.79 (standard error of the mean (SEM) = 0.07; 95% confi-
dence interval = 0.65 to 0.93; p = 0.001). For comparison, the
APACHE II score yielded an AUC value of 0.75 (SEM = 0.08;
95% confidence interval = 0.59 to 0.91; p = 0.005). A median
circulating Ang-2 of more than 11.08 ng/ml predicted death
with a specificity of 74% (95% confidence interval = 57 to 86)
and a sensitivity of 67% (95% confidence interval = 54 to 77).
The odds ratio for 30-day mortality was 5.6 (95% confidence
interval = 1.5 to 20.5), positive and negative predictive values
were 76% (95% confidence interval = 61 to 88) and 64%
(95% confidence interval = 49 to 75), respectively.
Figure 3 illustrates the Kaplan-Meier curves of 30-day survival
stratified to Ang-2 (less versus higher than median (11.08 ng/
ml)). Log rank test confirmed statistical significance for Ang-2
(p = 0.009). Accordingly, the hazard for Ang-2 (> median) in
Figure 2
Scatter plots showing correlations of results lots showing correlations of results. Correlations of Ang-2 
serum concentrations with (a) the Acute Physiology and Chronic 
Health Evaluation (APACHE) II score and (b) the Sequential Organ 
Failure Assessment (SOFA) score in 43 critically ill patients (non-septic 
patients (n = 14); severe sepsis (n = 12) and septic shock (n = 17)).Page 5 of 9
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group compared with the low Ang-2 group (≤ 11.08 ng/ml). Of
note, the 30-day survival of patients among the low Ang-2
group was 57%, while it was 20% in the group of patients with
high Ang-2 levels.
Discussion
The present study is a prospective clinical investigation of the
prognostic value of circulating Ang-2 as a biomarker in criti-
cally ill patients. The results are that: critically ill patients are
characterised by an excess of circulating Ang-2 in the pres-
ence of low Ang-1 and VEGF; Ang-2 correlates with severity
of illness (APACHE II and SOFA scores), pulmonary dysfunc-
tion (PaO2/FiO2 and PaO2) and tissue hypoxia (lactate); using
multivariate Cox proportional hazards regression analysis,
Ang-2 was identified as the only independent predictor for sur-
vival in our cohort of medical ICU patients.
As a Weibel-Palade body-stored molecule, Ang-2 is released
on endothelial stimulation by various factors, including comple-
ment, cytokines, fibrin, activated platelets and leucocytes, and
changes in oxygenation or blood flow [8,15]. Orfanos and col-
leagues [25] and Ganter and colleagues [22] reported that in
septic patients Ang-2 levels were associated with tumour
necrosis factor-alpha levels and systemic hypoperfusion,
respectively. In line with the latter finding, we detected a strong
Table 2
Univariate and multivariate Cox regression analysis
Univariate Multivariate
Variables HR 95% CI p value HR 95% CI P value
Age (years) 1.528 0.694 to 3.364 0.288
Gender (m/f) 1.007 0.983 to 1.031 0.577
Sepsis (yes/no) 2.688 0.918 to 7.874 0.072 1.004 0.154 to 6.553 0.997
MAP (mmHg) 0.981 0.954 to 1.009 0.186
Heart rate (bpm) 0.995 0.976 to 1.014 0.583
Noradrenaline (μg/kg/min) 1.433 0.695 to 2.954 0.330
FiO2 (%) 1.002 0.980 to 1.025 0.873
PaO2/FiO2 1.001 0.997 to 1.005 0.737
CRP (mg/L) 0.998 0.995 to 1.002 0.364
Lactate (mmol/L) 1.105 1.029 to 1.185 0.006* 1.064 0.986 to 1.148 0.111
APACHE II score 1.060 1.012 to 1.110 0.013* 1.040 0.985 to 1.099 0.154
SOFA score 1.107 1.006 to 1.219 0.038* 1.073 0.971 to 1.185 0.167
VEGF (pg/ml) 1.000 0.997 to 1.004 0.962
Ang-1 (ng/ml) 1.010 0.918 to 1.111 0.840
Ang-2 (ng/ml)a 1.034 1.013 to 1.056 0.001* 1.033 1.012 to 1.055 0.002*
Ang-2 (log10)a 4.383 1.628 to 11.802 0.003* 4.284 1.627 to 11.281 0.003*
Ang-2/Ang-1 (log10)a 2.630 1.207 to 5.729 0.015* 2.384 1.061 to 5.360 0.036* b
*p < 0.05.
a tested separately from each other;
b In this model APACHE II remained significant in the multivariate model (p = 0.039).
Ang = Angiopoietin; APACHE II = Acute Physiology and Chronic Health Evaluation II; CI = confidence interval; CRP = C-reactive protein; f = 
female; FiO2 = fraction of inspired oxygen; HR = heart rate; m = male; MAP = mean arterial pressure; PaO2 = partial pressure of oxygen in arterial 
blood; SOFA = Sequential Organ Failure Assessment; VEGF = vascular endothelial growth factor.Page 6 of 9
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Little is known about the regulation of Ang-1 in critically ill
patients. Experimental endotoxaemia has been shown to dis-
rupt protective Ang-1/Tie-2 signalling by reducing Ang-1 and
inducing Ang-2 expression [39]. In line with these results,
admission levels of Ang-1 were markedly decreased in our
patients. This finding is in apparent contrast to normal admis-
sion levels of Ang-1 in the aforementioned studies [22,23].
We assume that a decline in circulating Ang-1 is not an early
feature in critically ill patients, but might reflect ongoing illness,
as is often the case in medical patients compared with sudden
onset of impairment in surgical and trauma patients. This inter-
pretation fits with a recent cross-sectional study that showed
low Ang-1 concentrations after lengthier mechanical ventila-
tion in both, septic and non-septic ICU patients [21].
VEGF has been well characterised as an endothelial survival
factor that prevents microvascular apoptotic cell loss in vitro
[40]. In addition, the distinctive permeability-enhancing effects
of VEGF underlie a significant role of this protein in acute vas-
cular inflammation [41-43]. Both low and high VEGF concen-
trations have been found in critically ill patients, and its
significance is not completely understood [21,44,45]. VEGF
has been shown to modulate the effect of Ang-2 in a context-
dependent fashion: when levels of VEGF are high, Ang-2
causes disassembly of inter-endothelial cell-cell contacts,
whereas in the presence of low VEGF levels, Ang-2 induces
endothelial cell death and vessel regression [16]. The latter
constellation was present in our cohort, consistent with both a
leaky and apoptotic endothelial cell phenotype in sepsis
[1,46].
Consistent with previous reports, a strong positive correlation
between Ang-2 concentrations and APACHE II and SOFA
scores was detected in our cohort [23,25-27]. Thus it is rea-
sonable to assume that individual Ang-2 levels may reflect the
extent of activated endothelial surface among all organ-spe-
cific vascular beds at the same time.
In line with Parikh and colleagues [26] and van der Heijden
and colleagues [21], we found a significant association of high
Ang-2 concentrations with low PaO2/FiO2 and PaO2 values.
This supports the idea that excess Ang-2 is involved in the
increase in pulmonary permeability, leading to ARDS [26].
However, no correlation between EVLWI and Ang-2 or VEGF
was present in our cohort. Likewise, no correlation between
EVLWI and Ang-2 was detected by van der Heijden and col-
leagues [21]. EVLWI as a surrogate marker for endothelial is
probably an imperfect tool to detect permeability in mechani-
cally ventilated patients. Indeed, Ang-2 correlated with pulmo-
nary leak index assessed by the 67Gallium-labelled tranferrin
method [21]. Surprisingly, no such correlation could be
detected for CI, MAP, CVP, surrogate parameters of pre-load
(ITBVI) and after-load (SVRI), as well as for vasopressor sup-
port in the present study. These data reveal an important limi-
tation for Ang-2 as a quantitative marker for vascular
permeability: high Ang-2 might be a surrogate parameter for
increased capillary permeability per se, but is a poor marker for
the absolute extent of vascular 'leakiness'.
In contrast, we could identify Ang-2 as the strongest predictor
for survival in our cohort of medical ICU patients using a mul-
tivariate Cox model. In a large trauma cohort study [22], Ang-
2 correlated with mortality in a univariate analysis. In a surgical
population with ARDS, Ang-2 predicted death with a similar
discriminatory ability as the APACHE II score [23]. However,
none of the aforementioned studies tested the independent
predictive value of circulating Ang-2 compared with estab-
lished predictors of outcome using a multivariate model. Ang-
2 indeed outperformed the APACHE II and SOFA scores, as
well as several other predictors in our cohort. If validated in
larger cohorts, Ang-2 might be a promising new marker for
early outcome prediction and decision-making in critically ill
patients.
It should be pointed out that there are several limitations of our
study. The sample size of the present study was small and the
95% confidence intervals for AUC are still wide. Also, we
strictly included medical patients, thus our findings cannot be
extrapolated to postoperative or surgical patient population.
Future work will focus on the sensitivity and specificity
between Ang-2 levels, severity scores, various cytokines and
inflammatory markers in a larger ICU cohort including both,
medical and surgical patients.
Figure 3
Kaplan-Meier curves of survival stratified to Angiopoietin (Ang) 2l -Meier curves of survival s ratified to Angiopoieti  (Ang) 2. 
(less versus greater than median; Log rank test p = 0.009).Page 7 of 9
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In summary, a marked imbalance of the Ang/Tie system in
favour of circulating Ang-2 is correlated with severity of illness
and tissue hypoxia. High Ang-2 is probably a powerful inde-
pendent biomarker of adverse clinical outcome in medical ICU
patients. Further studies on the role of Ang-2 as a biomarker in
critically ill patients are warranted.
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